Related Experiment Videos
[Inhibitors of factor XIIIa].
1Klinikum der Friedrich-Schiller-Universität Jena, Zentrum für Vaskuläre Biologie und Medizin, Erfurt. prasa@zmkh.ef.uni-jena.de
Hamostaseologie
|August 24, 2002
Summary
Factor XIIIa (FXIIIa) stabilizes blood clots. FXIIIa inhibitors, including natural and synthetic compounds, offer potential therapeutic benefits by modulating its activity, as shown in animal studies.
Area of Science:
- Biochemistry
- Pharmacology
Context:
- Factor XIIIa (FXIIIa) is crucial for fibrin clot stabilization and resistance to degradation.
- FXIIIa also plays roles in wound healing and arteriosclerosis.
Purpose:
- To provide an overview of Factor XIIIa (FXIIIa) inhibitors.
- To discuss their mechanisms of action and therapeutic potential.
Summary:
- FXIIIa inhibitors include peptide analogues of natural substrates, naturally occurring compounds like tridegin, and synthetic small molecules.
- Synthetic inhibitors often covalently bind to the active site cysteine (Cys314) of FXIIIa.
- Specific inhibitors like azol derivatives and azolium salts demonstrate nanomolar potency.
Impact:
- FXIIIa inhibitors can be valuable tools for studying FXIIIa functions and developing pharmacological interventions.
- Combination therapy with FXIIIa inhibitors and plasminogen activators showed improved thrombolysis in animal models.